Comparative Pharmacology
Head-to-head clinical analysis: MPI STANNOUS DIPHOSPHONATE versus SODIUM FLUORIDE F 18.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI STANNOUS DIPHOSPHONATE versus SODIUM FLUORIDE F 18.
MPI STANNOUS DIPHOSPHONATE vs SODIUM FLUORIDE F-18
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stannous diphosphonate is a radiopharmaceutical agent that forms a complex with technetium-99m; it localizes to areas of increased bone turnover by chemisorption to hydroxyapatite crystals, thereby enabling bone scintigraphy.
Positron-emitting radionuclide used for bone imaging; fluoride ion is incorporated into bone matrix via chemisorption onto hydroxyapatite crystals, reflecting blood flow and osteoblastic activity.
Adult: 1-4 mg administered intravenously, single dose for bone scintigraphy.
2-10 mCi (74-370 MBq) intravenous bolus injection, single dose for positron emission tomography (PET) bone imaging.
None Documented
None Documented
Terminal elimination half-life: Approximately 2.5 hours for the diphosphonate component; the stannous ion is cleared more slowly. Clinically, this allows rapid bone uptake and background clearance for imaging within 2–4 hours post-injection.
The terminal elimination half-life is approximately 2-4 hours. Clinically, this allows for imaging within 1-3 hours post-injection.
Renal: >90% of the administered dose is excreted unchanged in the urine within 24 hours. Biliary/fecal: Minimal (<2%).
Renal (primarily). Approximately 70% of the administered dose is excreted unchanged in urine within 24 hours. Less than 10% is excreted in feces.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical